CatherineCCoombsMD

PubMed

• 92 citations
  Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.
  David P. Steensma, Martin Wermke, Virginia M. Klimek, Peter L. Greenberg, Patricia Font
  Leukemia. 2021-06-25
• 493 citations
  Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes.
  Catherine C. Coombs, Ahmet Zehir, Sean M. Devlin, Ashwin Kishtagari, Aijazuddin Syed
  Cell Stem Cell. 2017-09-07
• 175 citations
  Acute promyelocytic leukemia: where did we start, where are we now, and the future
  Catherine C. Coombs, Montreh Tavakkoli, Martin S. Tallman
  Blood Cancer Journal. 2015-04-17

Abstracts/Posters

• Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inh...
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Detection of Measurable Residual Disease (MRD) in Peripheral Blood: First Report of a Novel Microfluidic Platform in Patients with Acute Myeloid Leukemia (AML)
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all